Iradimed’s MRI Momentum: IRMD Pushes Q3 2026 Revenue Higher, Lifts Full-Year Guidance

Ticker: IRMD • Earnings: EPS, revenue forecast • earnings surprise (potential) • EPS consensus

Executive snapshot: IRMD’s Q3 2026 numbers and what they imply

IRADIMED CORPORATION (IRMD) reported a quiet-quarter growth story that management framed as momentum rather than a fluke. For the three months ended September 30, 2026, the company delivered revenue of $24.2 million, up from the year-ago period, with GAAP earnings per share (EPS) of $0.51 and non-GAAP EPS of $0.55. On a nine-month basis, IRMD tallied $66.6 million in revenue and $17.5 million in net income, translating to $1.37 in GAAP EPS and $1.50 in non-GAAP EPS for the period.

The company also launched a detailed revenue forecast for the full year 2026, guiding to $91.6 million to $93.1 million in revenue and GAAP EPS of $1.90 to $1.94, with non-GAAP EPS of $2.07 to $2.11. In other words, management is not just basking in a quarter’s performance; it’s leaning into a cautious but constructive growth path for the back half of 2026.

The press release does not publish an explicit EPS consensus figure or an analysts’ earnings surprise delta in the text, but the updated revenue forecast and EPS ranges imply the company sees continued progress versus prior run-rates. Investors will compare these numbers against street expectations as they come to market, a classic “earnings surprise” lens even if not labeled as such in the filing.

What’s driving the quarter: product momentum and bookings

A centerpiece of IRMD’s growth narrative is its MRI-compatible, non-magnetic IV infusion pumps. The company highlighted the continued rollout of its 3870 MR IV pump platform and noted that, in the quarter, roughly 70% of pump bookings were for the “quad stack” configuration—four pumps on a single pole. That configuration represents a meaningful acceleration in pump channels per installation, signaling a customer push to standardize around higher-capacity, MRI-friendly equipment.

The quarterly results also show margin and revenue contributions from this platform as the company gains production experience and scales volumes. Management pointed to record bookings and a strengthening gross margin as signals that the operating leverage embedded in the newer platform is starting to translate into the P&L.

Outlook: what the forecast may portend for IRMD and peers

Beyond the numbers, the forward-looking guidance matters. IRMD’s $91.6–$93.1 million revenue forecast and corresponding GAAP/EPS ranges suggest confidence in continued demand for MRI-compatible devices and the 3870 platform’s ability to sustain growth into year-end. If demand sustains, repeat orders could underpin a more stable top line, which in a patient-goods space often translates to steadier cash flow and a more predictable cost base.

For sector peers, IRMD’s emphasis on higher-channel configurations—successfully integrating more pumps per MRI setup—serves as a conceptual playbook: product differentiation through MRI compatibility, coupled with scalable manufacturing, can create a moat of sorts in a specialized medical-device niche. However, the MRI equipment ecosystem remains exposed to hospital capex cycles, reimbursement environments for devices, and the ongoing supply-chain cadence that can compress or extend revenue recognition. The balance of demand for non-magnetic devices in MR environments and the pace at which customers adopt higher-capacity configurations will likely be a key driver for peers in this space.

Dividends and capital returns: a steady rhythm

In a nod to shareholder returns amid growth, IRMD’s board declared a regular quarterly cash dividend of $0.20 per share for the third quarter of 2026. The dividend is payable November 27, 2026 to stockholders of record as of November 13, 2026. The persistence of this payout underscores a governance posture that balances growth investments with predictable cash returns.

Takeaways for investors and sector peers

IRMD’s Q3 narrative emphasizes a combination of product innovation, operational execution, and strategic monetization of a higher-channel pump portfolio. The 3870 MR IV pump and the quad-stack configuration appear to be resonating with customers seeking MRI-friendly, scalable infusion solutions. The revenue forecast lift, paired with a roughly flat-to-upbeat EPS trajectory, paints a path where IRMD can continue to translate volume into earnings growth, provided market demand holds and manufacturing scales smoothly.

For analysts and peers, the key questions will be: will the MRI environment sustain its demand trajectory, and can IRMD maintain its margin trajectory as production scales? The answers will influence how the broader MRI-adjacent medical-device cohort prices and defends its market share in a period of healthcare capital discipline.

Notes and context

The filing reflects results for the three and nine months ended September 30, 2026, and includes a forward-looking revenue forecast and EPS guidance for the full year. It also highlights non-GAAP metrics, which IRMD uses to illustrate ongoing operating performance by excluding stock-based compensation and other items. The company remains focused on non-magnetic, MRI-compatible device offerings that are designed to perform in the presence of strong magnetic fields.